Denali Therapeutics Inc.

Denali Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing therapeutics for neurodegenerative and lysosomal storage diseases. Its pipeline includes programs targeting various conditions: Eclitasertib (SAR443122/DNL758) for peripheral inflammatory diseases, BIIB122/DNL151 for Parkinson's disease, TAK-594/DNL593 for frontotemporal dementia-granulin, DNL126 for MPS IIIA (Sanfilippo Syndrome A), and DNL310 (Tividenofusp alfa) for MPS II (Hunter Syndrome). The company also has Enzyme TransportVehicle (TV) programs like DNL952 for Pompe disease, and other programs such as DNL111 for Parkinson's and Gaucher diseases, DNL622 for Hurler syndrome (MPS I), DNL628 targeting tau for Alzheimer's disease, DNL422 targeting alpha synuclein for Parkinson's disease, and DNL921 targeting Abeta for Alzheimer's disease.

Denali Therapeutics Inc. is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol DNLI. The trading currency is the US Dollar (USD), as the company is based in the United States. The exchange is one of the major US stock exchanges, providing liquidity and visibility for investors.

Denali Therapeutics operates in the Healthcare sector, specifically within the Biotechnology industry. As a biopharmaceutical company, it focuses on developing therapies for complex diseases such as neurodegenerative disorders and lysosomal storage diseases. Biotechnology companies like Denali use biological processes and genetic engineering to create treatments, often targeting conditions with high unmet medical needs.

Denali Therapeutics Inc. is headquartered in South San Francisco, California, United States. The company was incorporated in 2013 and was formerly known as SPR Pharma Inc. before rebranding to Denali Therapeutics in March 2015. Its location in the San Francisco Bay Area places it within a major biotechnology hub, providing access to talent, research institutions, and potential partners.

Denali Therapeutics has a diverse pipeline targeting neurodegenerative and lysosomal storage diseases. Key programs include Eclitasertib (SAR443122/DNL758) for peripheral inflammatory diseases, BIIB122/DNL151 for Parkinson's disease, TAK-594/DNL593 for frontotemporal dementia-granulin, DNL126 for MPS IIIA, and DNL310 (Tividenofusp alfa) for MPS II. The company also develops Enzyme TransportVehicle (TV) programs such as DNL952 for Pompe disease, and other programs like DNL111 for Parkinson's and Gaucher diseases, DNL622 for Hurler syndrome, DNL628 targeting tau for Alzheimer's disease, DNL422 targeting alpha synuclein for Parkinson's disease, and DNL921 targeting Abeta for Alzheimer's disease. These programs utilize proprietary technology platforms to deliver therapeutics across the blood-brain barrier.